enGene Therapeutics (ENGN) vs Innate Pharma S.A. (IPHA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Innate Pharma S.A. (IPHA) has outperformed enGene Therapeutics (ENGN) over the past year, losing 52.6% versus a loss of 75.0%. enGene Therapeutics is the larger company by market cap ($116.6 million vs $96.4 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENGN | IPHA |
|---|---|---|
| Share price | $1.74 | $0.8634 |
| Market cap | $116.61M | $96.44M |
| 1-day change | -1.14% | -8.14% |
| YTD return | -80.73% | -50.66% |
| 1-year return | -75.00% | -52.56% |
| 5-year return | — | -82.01% |
| EPS (TTM) | $-2.07 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-117.30M | — |
| 52-week high | $12.25 | $2.71 |
| 52-week low | $1.40 | $0.829 |
| Distance from 52-week high | -85.80% | -68.14% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +146.55% | +826.57% |
| Average volume | 1.12M | 42.76K |
| Shares outstanding | 67.02M | 111.70M |
| Employees | 81 | 120 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IPHA has outperformed ENGN by 22.4 percentage points over the past year.
About enGene Therapeutics
ENGN stock →enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees
About Innate Pharma S.A.
IPHA stock →Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 120 employees
ENGN vs IPHA FAQ
Which is bigger, enGene Therapeutics or Innate Pharma S.A.?
enGene Therapeutics (ENGN) is larger, with a market capitalization of $116.61M compared with $96.44M for Innate Pharma S.A. (IPHA).
Which stock has performed better over the past year, ENGN or IPHA?
IPHA returned -52.56% over the past 12 months, compared with -75.00% for ENGN (price return, excluding dividends). Past performance does not predict future results.
Are enGene Therapeutics and Innate Pharma S.A. in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.